LOGIN  |  REGISTER
Amneal Pharmaceuticals
C4 Therapeutics

Regional Health Properties Announces Commencement of Trading of Series B Preferred Stock on OTC Markets

August 03, 2023 | Last Trade: US$2.77 0.00 0.00

ATLANTA, GA, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Regional Health Properties, Inc. (the “Company”) (NYSE American: RHE) (NYSE American: RHE-PA) (OTCQB Venture: RHEPB), a self-managed healthcare real estate investment company that invests primarily in real estate purposed for senior living and long-term care, announced today that its 12.5% Series B Cumulative Redeemable Preferred Shares (the “Series B Preferred Stock”) commenced trading on the OTCQB Venture Market, operated by the OTC Markets Group, Inc., under the symbol “RHEPB”.

The Company’s Common Stock and Series A Redeemable Preferred Shares will continue to trade on the NYSE American LLC under the symbols “RHE” and “RHE-PA,” respectively. The Company will continue to file its required periodic reports and other filings with the Securities and Exchange Commission.

About Regional Health Properties

Regional Health Properties, Inc., a Georgia corporation, is a self-managed healthcare real estate investment company that invests primarily in real estate purposed for senior living and long-term care. For more information, visit www.regionalhealthproperties.com.

 
Company Contact
 

Brent Morrison, CFA
Chief Executive Officer & President
Regional Health Properties, Inc.
Tel (678) 368-4402
This email address is being protected from spambots. You need JavaScript enabled to view it.

C4 Therapeutics

Stock Quote

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page